Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CAP Drugs Must Meet Stricter Noninferiority Criteria Under Draft FDA Guidance

Executive Summary

Biopharma firms developing drugs to treat community acquired pneumonia would be wise to follow the specifications FDA has set forth in a new 1draft guidance on the subject. The guidance specifies strict criteria for patient selection and confirmation of infection to support an evaluation based on noninferiority margins

You may also be interested in...



FDA Indicates Flexibility On Evidence To Support Efficacy In Pneumonia

The agency will seek advisory panel input Nov. 3-4 on options for facilitating trials in community-, hospital- and ventilator-acquired pneumonia.

Pneumonia Guidances Revisited: FDA Cmte. To Weigh Study Design Issues Again

FDA’s Anti-Infective Drugs Advisory Committee will take its third look in less than four years at standards for developing antibacterial agents to treat community-acquired bacterial pneumonia, at a meeting on Nov. 3.

Pneumonia Guidances Revisited: FDA Cmte. To Weigh Study Design Issues Again

FDA’s Anti-Infective Drugs Advisory Committee will take its third look in less than four years at standards for developing antibacterial agents to treat community-acquired bacterial pneumonia, at a meeting on Nov. 3.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel